Physician profile
Edward J Busick
NPI 1467436931
$3,640.30
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,491 · 2020: $958 · 2021: $1,192.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $581.30 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $445.08 | 2019-2021 | |
| Pfizer INC. | $365.94 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $263.53 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $238.26 | 2019-2021 | |
| Lilly USA, LLC | $189.08 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $181.94 | 2019-2021 | |
| Amarin Pharma, INC. | $166.01 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.25 | 2019-2021 | |
| Lifescan, INC. | $142.57 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $115.18 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.80 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $101.08 | 2019 | |
| Merck Sharp & Dohme LLC | $95.35 | 2020-2021 | |
| Radius Health, INC. | $87.81 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $83.50 | 2020-2021 | |
| Valeritas, INC. | $77.52 | 2019 | |
| Vanda Pharmaceuticals INC. | $52.70 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $36.72 | 2019-2020 | |
| Dexcom, INC. | $34.78 | 2019 | |
| Novo Nordisk INC | $34.36 | 2021 | |
| Acerus Pharmaceuticals Corporation | $26.24 | 2020 | |
| Glaxosmithkline, LLC. | $22.30 | 2020 | |
| Corcept Therapeutics | $20.85 | 2019 | |
| Astellas Pharma US INC | $15.09 | 2021 | |
| Medtronic Minimed, INC. | $15.06 | 2019 |
3 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Busick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.